scholarly journals Men’s health and osteoporosis: modern treatment and prevention options

2022 ◽  
pp. 120-129
Author(s):  
E. V. Biryukova ◽  
M. V. Shinkin
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Bone Mass Loss ◽  
Treatment And Prevention ◽  
Modern Health Care ◽  
Common Causes ◽  
Clinical Consequences ◽  
The Moment ◽  
Linear Manner ◽  
Current Guidelines

Osteoporosis (OP) has traditionally been seen as a pathology that mainly occurs in postmenopausal women and elderly men, and until recently, the problem of this disease among males has not been given sufficient priority. At the moment, however, OP in men is widely acknowledged to be an important issue of modern health care. Given the etiological and pathogenetic characteristics, two categories of OP have been identified: primary and secondary. In the structure of male OP, the secondary category of OP accounts for up to 40-60 % of all cases. Hypogonadism is one of the common causes of bone loss in men. Initially, males develop a larger bone mass compared to women and, accordingly, greater bone strength. Men over the age of 50 do not undergo rapid bone mass loss, as women do after menopause, and the bone mass decreases more gradually, in a linear manner. With ageing, the trabecular number (Tb.N) in men are relatively maintained with underlying more pronounced thinning of Tb. N associated with decreased osteoblast-forming activity. Although the prevalence of OP among men is significantly lower than among women, the clinical consequences of OP in men are of a great importance. The primary strategy of the anti-osteoporotic therapy is to prevent OP and low-traumatic fractures. According to the current guidelines for the treatment of OP in men, bisphosphonates (BP) are the drugs of choice. Zoledronic acid is a highly effective nitrogen-containing BP, the first drug to be injected once a year. Intravenous injection of zoledronic acid is as effective in reducing the risk of fractures in men as in women.

Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats

2021 ◽  
pp. 153537022110110
Author(s):  
Yu-Ting Cheng ◽  
Jian Liao ◽  
Qian Zhou ◽  
Hua Huo ◽  
Lucas Zellmer ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Mass Loss ◽  
Ovariectomized Rats ◽  
Therapeutic Effects ◽  
Bone Mass Loss ◽  
Cellular Effects ◽  
Protein Levels ◽  
Adverse Factor ◽  
Osteoclast Apoptosis

Bone mass loss (osteoporosis) seen in postmenopausal women is an adverse factor for implant denture. Using an ovariectomized rat model, we studied the mechanism of estrogen-deficiency-caused bone loss and the therapeutic effect of Zoledronic acid. We observed that ovariectomized-caused resorption of bone tissue in the mandible was evident at four weeks and had not fully recovered by 12 weeks post-ovariectomized compared with the sham-operated controls. Further evaluation with a TUNEL assay showed ovariectomized enhanced apoptosis of osteoblasts but inhibited apoptosis of osteoclasts in the mandible. Zoledronic acid given subcutaneously as a single low dose was shown to counteract both of these ovariectomized effects. Immunohistochemical staining showed that ovariectomized induced the protein levels of RANKL and the 65-kD subunit of the NF-κB complex mainly in osteoclasts, as confirmed by staining for TRAP, a marker for osteoclasts, whereas zoledronic acid inhibited these inductions. Western blotting showed that the levels of RANKL, p65, as well as the phosphorylated form of p65, and IκB-α were all higher in the ovariectomized group than in the sham and ovariectomized + zoledronic acid groups at both the 4th- and 12th-week time points in the mandible. These data collectively suggest that ovariectomized causes bone mass loss by enhancing apoptosis of osteoblasts and inhibiting apoptosis of osteoclasts. In osteoclasts, these cellular effects may be achieved by activating RANKL-NF-κB signalling. Moreover, zoledronic acid elicits its therapeutic effects in the mandible by counteracting these cellular and molecular consequences of ovariectomized.

scholarly journals A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis

2009 ◽  
Vol 11 (6) ◽  
pp. R185 ◽  
Author(s):  
Benoit Le Goff ◽  
Elise Soltner ◽  
Céline Charrier ◽  
Yves Maugars ◽  
Françoise Rédini ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Mass Loss ◽  
Collagen Induced Arthritis ◽  
Bone Mass Loss ◽  
Bone Erosions

scholarly journals Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy

Cells ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1895
Author(s):  
Francesca Marini ◽  
Francesca Giusti ◽  
Federica Cioppi ◽  
Davide Maraghelli ◽  
Tiziana Cavalli ◽  
...  
Keyword(s):  
Primary Hyperparathyroidism ◽  
Bone Mass ◽  
Bone Metabolism ◽  
Mineral Metabolism ◽  
Parathyroid Tissue ◽  
Young Patients ◽  
Surgical Removal ◽  
Mineral Density ◽  
Bone Mass Loss ◽  
Before And After

Primary hyperparathyroidism (PHPT) is the most common endocrinopathy in multiple endocrine neoplasia type 1 (MEN1). Persistent levels of increased parathyroid hormone (PTH) result in a higher incidence of osteopenia and osteoporosis compared to the general population. Surgical removal of hyper-functioning parathyroid tissue is the therapy of choice. This retrospective study evaluated the effect of parathyroidectomy (PTX) on bone metabolism and bone mass in two series of patients with MEN1 PHPT and sporadic PHPT (sPHPT) by comparing bone metabolism-related biochemical markers and bone mineral density (BMD) before and after surgery. Our data confirmed, in a higher number of cases than in previously published studies, the efficacy of PTX, not only to rapidly restore normal levels of PTH and calcium, but also to normalize biochemical parameters of bone resorption and bone formation, and to improve spine and femur bone mass, in both MEN1 PHPT and sPHPT. Evaluation of single-patient BMD changes after surgery indicates an individual variable bone mass improvement in a great majority of MEN1 PHPT patients. In MEN1 patients, PTX is strongly suggested in the presence of increased PTH and hypercalcemia to prevent/reduce the early-onset bone mass loss and grant, in young patients, the achievement of the bone mass peak; routine monitoring of bone metabolism and bone mass should start from adolescence. Therapy with anti-fracture drugs is indicated in MEN1 patients with BMD lower than the age-matched normal values.

scholarly journals Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma

Blood ◽  
2017 ◽  
Vol 129 (26) ◽  
pp. 3452-3464 ◽  
Author(s):  
Michelle M. McDonald ◽  
Michaela R. Reagan ◽  
Scott E. Youlten ◽  
Sindhu T. Mohanty ◽  
Anja Seckinger ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Zoledronic Acid ◽  
Bone Mass ◽  
Fracture Resistance ◽  
Specific Protein ◽  
Key Points

Key Points Anti-sclerostin treatment increases bone mass and fracture resistance in MM Anti-sclerostin in combination with zoledronic acid is superior to zoledronic acid alone in increasing fracture resistance.

scholarly journals Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism

Endocrinology ◽  
2017 ◽  
Vol 158 (11) ◽  
pp. 3765-3777 ◽  
Author(s):  
Elena Tsourdi ◽  
Franziska Lademann ◽  
Michael S Ominsky ◽  
Eddy Rijntjes ◽  
Josef Köhrle ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Male Mice

Miscarriage in patients with chronic endometritis and luteal phase deficiency. Principles of treatment and prevention

2021 ◽  
Vol 20 (1) ◽  
pp. 55-63
Author(s):  
T.A. Pluzhnikova ◽  
◽  
E.A. Mikhnina ◽  
V.A. Kazantsev ◽  
V.F. Bezhenar ◽  
...  
Keyword(s):  
Luteal Phase ◽  
Recurrent Miscarriage ◽  
Embryo Implantation ◽  
Patient Treatment ◽  
Chronic Endometritis ◽  
Treatment And Prevention ◽  
Tissue Changes ◽  
Principles Of Treatment ◽  
Group 2 ◽  
The Moment

Permanent inflammation of the endometrium against the background of altered vaginal microbiota is accompanied by a violation of cyclic tissue changes. The revealed deficiency of the secretory phase of the cycle was formed independently of the synthesis of progesterone by the corpus luteum and led to impaired embryo implantation and miscarriage. Objective. To evaluate the efficiency of dydrogesterone in miscarriage in patients with chronic endometritis (CE) with luteal phase deficiency. Patients and methods. The study involved 127 women aged 25 to 40 years non-pregnant and during pregnancy with biopsyverified deficiency of the luteal phase of the cycle and CE of varying degrees of activity according to immunohistochemistry data. Women from group 1 (n = 83) continuously received dydrogesterone in a cyclic regimen from the moment of diagnosis until the 21st week of pregnancy; women from group 2 (n = 44) received dydrogesterone for 4 months of CE treatment, then it was discontinued and resumed again from the onset of pregnancy until the 21st week. Conclusion. There was no normalization of the structure of the endometrium after CE treatment with dydrogesterone removal from therapy in women with miscarriage and deficiency of the luteal phase of the cycle. Administration of dydrogesterone in a cyclic regimen with pregravid preparation before pregnancy, regardless of the initial level of progesterone in the blood, by women with miscarriage, CE and luteal phase deficiency contributes to normalization of morphological state of the endometrium in most patients, to significant decrease in the frequency of early miscarriage and duration of in-patient treatment, in contrast to women who canceled dydrogesterone. Key words: dydrogesterone, luteal phase deficiency, recurrent miscarriage, chronic endometritis

Brain death in pregnancy: what will be left of the life of foetus?

2020 ◽  
Vol 69 (3) ◽  
pp. 281-291
Author(s):  
Matteo Gulino ◽  
Gianluca Montanari Vergallo ◽  
Rosagemma Ciliberti ◽  
Antonio G. Spagnolo
Keyword(s):  
Brain Death ◽  
Human Life ◽  
Rare Event ◽  
High Impact ◽  
Social Implications ◽  
Vital Functions ◽  
Clinical Consequences ◽  
Potential Impact ◽  
The Moment ◽  
In Pregnancy

Brain death in pregnancy (BDinP) has been described in literature as a “rare event” and “hopeless condition for patients”, who has a devastating potential to negatively affect the poetry of the moment of welcoming a new human life to the world. Clinical consequences of BDinP are extremely dangerous for the life of a foetus that, without prompt medical actions, is doomed to suffer the same fate as the mother. Modern medical techniques make it possible to maintain basic vital functions of the pregnant woman for months, in order to achieve a level of development of the foetus. Although maternal somatic support requires the consideration of specific medical parameters, from a bioethical standpoint, this option gives rise to multiple ethical and social implications. In this manuscript, we identify the main ethical and social implications about maternal somatic support, including the potential impact on the clinical practice of medical staff, and discuss some Italian high-impact media cases.* The authors contributed equally to the work.

Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment

2012 ◽  
Vol 24 (7) ◽  
pp. 2127-2132 ◽  
Author(s):  
A. D. Anastasilakis ◽  
S. A. Polyzos ◽  
P. Makras ◽  
A. Gkiomisi ◽  
M. Savvides ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Acid Treatment ◽  
Activin A ◽  
Low Bone Mass
Sign in / Sign up

Export Citation Format

Share Document